Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Pieter H, Anborgh"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Green, photosynthesizing plants can be proficiently used as cost-effective, single-use, fully biodegradable bioreactors for environmentally-friendly production of a variety of valuable recombinant proteins. Being near-infinitely scalable and
Externí odkaz:
https://doaj.org/article/35ea501904714ad5a8da2e4fdc5dc366
SUMMARYDevelopment of efficient therapies for COVID-19 is the focus of intense research. The cytokine release syndrome was underlined as a culprit for severe outcomes in COVID-19 patients. Interleukin-6 (IL-6) plays a crucial role in human immune res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e484c9bace513525610dd80276c5e880
https://doi.org/10.1101/2021.09.14.460246
https://doi.org/10.1101/2021.09.14.460246
Autor:
Milica Krstic, Alan B. Tuck, Pieter H. Anborgh, Ann F. Chambers, Haider M. Hassan, Bart Kolendowski, Joseph Torchia, Carl O. Postenka, M. Nicole Hague
Publikováno v:
Laboratory Investigation; a Journal of Technical Methods and Pathology
TBX3 is a member of the highly conserved family of T-box transcription factors involved in embryogenesis, organogenesis and tumor progression. While the functional role of TBX3 in tumorigenesis has been widely studied, less is known about the specifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07dd4bd86bad43df5ada8645fe8f1b4c
http://europepmc.org/articles/PMC7044113
http://europepmc.org/articles/PMC7044113
Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer
Publikováno v:
Expert opinion on therapeutic targets. 22(8)
Effective targeted therapies for patients with triple-negative breast cancer (TNBC) present an unmet clinical need. There is evidence that TNBCs often have increased expression of the epidermal growth factor receptor (EGFR) and of osteopontin (OPN).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9251d331f24efadc655ba42dde26731f
https://pubmed.ncbi.nlm.nih.gov/30025479
https://pubmed.ncbi.nlm.nih.gov/30025479
Autor:
A. Dal Pra, K Chadwick, Eva Christensen, Pieter H. Anborgh, Charles Catton, Robert G. Bristow, Cynthia Ménard, Neil Fleshner, Ann F. Chambers, Melania Pintilie, Michael Milosevic, John Thoms
Publikováno v:
British Journal of Cancer
Background: High plasma osteopontin (OPN) has been linked to tumour hypoxia, metastasis, and poor prognosis. This study aims to assess whether plasma osteopontin was a biomarker of increasing progression within prostate cancer (PCa) prognostic groups
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce3bcdb4e8eb19faf25592f1002b1aca
http://europepmc.org/articles/PMC3425969
http://europepmc.org/articles/PMC3425969
Autor:
J-A Chapman, L. Han, Lois E. Shepherd, Colin H Wilson, Alan B. Tuck, Carl O. Postenka, Ann F. Chambers, Vivien H.C. Bramwell, Michael Pollak, Pieter H. Anborgh, Kathleen I. Pritchard
Publikováno v:
Cancer Research. 71:P2-12
Background We have shown, in women with metastatic breast cancer (BC), that high baseline plasma osteopontin (OPN) levels and increases over time are associated with poor survival. In primary BC, increased immunohistochemical (IHC) expression of OPN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59ca160de3506adf66e62aaedbbaa771
https://doi.org/10.1158/0008-5472.sabcs11-p2-12-28
https://doi.org/10.1158/0008-5472.sabcs11-p2-12-28
Publikováno v:
Journal of Cell Communication and Signaling. 5:111-122
Osteopontin (OPN) is a matricellular protein that binds to a number of cell surface receptors including integrins and CD44. It is expressed in many tissues and secreted into body fluids including blood, milk and urine. OPN plays important physiologic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa5fa38fe2e3b6fecb078eaf4447d650
https://doi.org/10.1007/s12079-011-0130-6
https://doi.org/10.1007/s12079-011-0130-6
Publikováno v:
Journal of Cellular and Molecular Medicine
Osteopontin (OPN) is a secreted protein present in bodily fluids and tissues. It is subject to multiple post-translational modifications, including phosphorylation, glycosylation, proteolytic cleavage and crosslinking by transglutamination. Binding o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4766ebed7921c16cc21891a521c830af
https://doi.org/10.1111/j.1582-4934.2010.01115.x
https://doi.org/10.1111/j.1582-4934.2010.01115.x
Autor:
Alan B. Tuck, Nancy Schmidt, Pieter H. Anborgh, Eric Winquist, Russell Hart, Sylvia M. Wilson, Toshimitsu Uede, Shigeyuki Kon, Larry Stitt, Ann F. Chambers, Masahiro Maeda
Publikováno v:
Clinical Chemistry. 55:895-903
Background: A previously developed monoclonal/polyclonal ELISA (Mono/Poly) to detect plasma concentrations of osteopontin (OPN) was shown to provide prognostic information in breast, prostate, and other cancers. Here we describe the clinical validati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0eda345fd79376b1768039447813d60
https://doi.org/10.1373/clinchem.2008.117465
https://doi.org/10.1373/clinchem.2008.117465
Autor:
Pieter H, Anborgh, Laura Br, Caria, Ann F, Chambers, Alan B, Tuck, Larry W, Stitt, Muriel, Brackstone
Publikováno v:
American journal of translational research. 7(4)
Osteopontin (OPN), a malignancy-associated secreted phosphoprotein, is a prognostic plasma biomarker for survival in metastatic breast cancer patients. We evaluated the role of OPN in Locally Advanced Breast Cancer (LABC) patients in predicting respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::edf90019e58fdd10656c5dc4abd396fa
https://pubmed.ncbi.nlm.nih.gov/26064440
https://pubmed.ncbi.nlm.nih.gov/26064440